Health News Releases

  • Today May 17
BeOne Medicines' flagship U.S. biologics manufacturing and clinical R&D facility at the Princeton W
May 15, 15:30
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
BeOne Medicines Ltd. (https://beonemedicines.com/) (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has gr
Aster Guardians Global Nursing Awards 2026 - Top 10 Finalists (Photo: AETOSWire)
May 15, 11:30
Aster Guardians Global Nursing Award Announces Top 10 Finalists for 2026
On the occasion of International Nurses Day, Aster DM Healthcare has announced the Top 10 finalists for the fifth edition of the Aster Guardians Global Nursing Award 2026, selected from over 134,000 r
Signing ceremony with imec held on April 9
May 14, 10:10
Rigaku Accelerates Next-generation Semiconductor Metrology Development Leveraging World-Class Research Infrastructure
Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; “Rigaku”), announced the
May 14, 09:30
Angelalign Technology Inc. (6699.HK) Applauds European Court Rejection of Patent Infringement Claim
Angelalign Technology Inc. (6699.HK) (“Angel”) (http://www.angelaligner.com) today said it was grateful that the Local Division Düsseldorf (Germany) of the Unified Patent Court rejected a request by A
Oral B Announces The Big Rethink 2026, Launching One of Europe’s Largest Disability Focused Oral Hea
May 13, 16:26
Oral‑B Announces The Big Rethink 2026, Launching One of Europe’s Largest Disability‑Focused Oral Health Studies
Oral B today announces The Big Rethink 2026, the next evolution of its flagship oral health inclusion programme, developed in partnership with the International Association for Disability and Oral Hea
May 13, 16:11
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54533184&newsitemid=20260510786927&lan=en-US&anc
May 12, 14:30
HistoSonics Moves to Advance Additional Histotripsy Applications Announcing FDA Submission for Kidney Tumors
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced it has submitted a De Novo request to the U.S. Food and Drug Administration seeking
May 12, 10:15
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G pTau 217 Plasma Assay
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the Regulatio
Urethral stricture starts with narrowing of a short segment of urethral lumen. At early stages, it i
May 11, 16:50
Pioneering feat in regenerative medicine, the BEES-HAUS cell therapy: Paracrine effect and cell engraftment, together healing urethral stricture. Its simplified version, BHES-HAUS’ results to be presented in AUA 2026
A path breaking scientific discovery, unraveling successful wound healing mechanism in urethral stricture with BEES-HAUS (https://www.ncrm.org/myth/beeshaus/) cell therapy has been reported by Indo-Ja
May 10, 15:25
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates
BeOne Medicines Ltd. (https://beonemedicines.com/) (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the first quarter of
WHOOP Expands Health Platform with On-Demand Clinician Access and New AI Features
May 10, 13:30
WHOOP Expands Health Platform with On-Demand Clinician Access and New AI Features
WHOOP (https://www.whoop.com/kr/en/?utm_source=PR&utm_medium=PR&utm_campaign=SR_A), the human performance company, today announced a new suite of health and AI-driven enhancements and feature updates
HE Mansoor Al Mansoori (Left) and Tom Hale (Right)
May 08, 16:50
Department of Health - Abu Dhabi and ŌURA Partner to Advance Preventive Health in Abu Dhabi
Department of Health—Abu Dhabi (https://www.doh.gov.ae/en/) (DoH) and ŌURA (https://ouraring.com/ko?srsltid=AfmBOormyEZs4LuQCQfSGbmxbAuvAy4qBM3q7akrgnjiPIzDNqS2nZh9), maker of the world’s leading smar
May 06, 16:25
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), m
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Mo
May 04, 16:00
TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Wid
May 03, 17:20
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership
CorFlow Therapeutics AG (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.corflow.com&esheet=54526078&newsitemid=20260430413675&lan=en-US&anchor=CorFlow+Therapeutics+AG&index=1&md5
May 03, 16:00
MRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcerative Colitis
MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that MH
May 03, 11:40
SS&C Unveils WorkHQ to Power Enterprise Agentic Automation
SS&C Technologies Holdings, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ssctech.com%2F%3Futm_campaign%3DSSC2026-Enterprise-Press-Release-0426%26utm_medium%3Dpressreleas
May 03, 11:00
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54524717&newsitemid=20260429582815&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
May 03, 10:40
SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 2024
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it filed its annual report on Form 20-F for the fiscal
David Weinreich, Global Head of R&D and Chief Medical Officer
May 03, 10:20
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481 (https://cts.businesswire.com/ct/CT?id=smartlink&url=h
Masimo RD SET® Neo Pulse Oximetry Sensor
April 30, 16:10
Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study
Masimo (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.masimo.com&esheet=54524005&newsitemid=20260428136753&lan=en-US&anchor=Masimo&index=1&md5=9061676d45e4b2fdccbe6887499605e3)
Dr. Vivek Mundada with Medcare multidisciplinary medical team (Photo: AETOSWire)
April 30, 09:40
Dubai’s Medcare Hospital Becomes the World’s First to Treat an Adult Spinal Muscular Atrophy (SMA) Patient Outside the US
Medcare Royal Speciality Hospital (MRSH) in Dubai has become the world’s first hospital outside the USA, to offer a newly licensed intrathecal gene therapy - Itvisma, to adult patients with Spinal Mus
Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equi
April 30, 08:55
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio
Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc. (“KalVista”) (Nasdaq: KALV), today announced that the compan
Credits to Roquette
April 29, 17:15
Roquette Showcases Its Expanded Consumer Healthcare Capabilities at Vitafoods Europe 2026
Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, will present its expanded portfolio at Vitafoods Europe 2026 which is taking place from May 5 to May 7 in
April 29, 13:13
Samsung Bioepis and ATLATL Sign Memorandum of Understanding (MoU) to Accelerate Early-Stage Biotech Innovation in Asia-Pacific
Samsung Bioepis Co., Ltd. and ATLATL Innovation Center (hereinafter referred to as “ATLATL”), global innovation platform for life science research and development, today announced that the companies h
PCI Pharma Services announced a series of major infrastructure investments that substantially deepen
April 28, 16:00
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities
PCI Pharma Services (“PCI”) - a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies - announced a ser
April 28, 15:40
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients
Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adu
Sun Pharma signs Definitive Agreement to Acquire Organon
April 28, 15:30
Sun Pharma signs Definitive Agreement to Acquire Organon
Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (N
Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt
April 27, 15:20
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health
Today, the Higher Regional Court of Frankfurt upheld the February 2025[1] partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia
First-in-human contrast enhanced MRI images with GE HealthCare’s mangaciclanol
April 24, 13:51
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents
GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI)
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
April 24, 11:10
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
Agenus (https://www.agenusbio.com/) Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, and BAP Pharma (https://bappharma.com/), a global medicines access and clinical trial supply company, t
April 23, 16:33
Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026. · Strong start to the year delivering net sales of 1,47
April 23, 15:51
Galderma Shareholders Approve All Annual General Meeting Proposals
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, announced that shareholders approved all proposals put forward by the Board of Directors at its Annual General Meeting (AGM), h
April 23, 15:00
Crown Bioscience and Turbine Partner to Connect AI-Driven Prediction with Organoid Validation in Translational Oncology
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announced a strategic partnership with Turbine, a leading virtual biology company, to advance tra
Double Logo
April 22, 11:10
Rigaku Enters Strategic Alliance with Onto Innovation through 27 % Equity Investment
Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), a global leader in X-ray analytical technologies, today announced that it has entered into a str
PETG PharmaTainer™ bottles and carboys—RNase/DNase-free, ultra-clean, ready-to-use containers for bi
April 21, 15:30
Cleaner by Design: SaniSure Introduces PETG PharmaTainer™ Ultra-Clean Bottles & Carboys
SaniSure® today announced the launch of PETG PharmaTainer™, a new line of bioprocessing bottles and carboys combining widely accepted, medical-grade Eastman Eastar® PETG 6763 resin (DMF#9987) with San
April 21, 10:15
SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced t
Electron microscope image of BK virus, showing the VP1 capsid protein that creates an icosahedral sh
April 20, 09:35
Orthogon Therapeutics Raises an Additional $11M Financing for Its BK Virus Antiviral Drug Program
Orthogon Therapeutics today announced the closing of a follow-on $11 million financing, bringing its total capital raised to $36 million. This financing supports the continued advancement of its first
April 19, 14:55
Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 2026
Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, will profile the Company’s first-in-class antifolate and phosphonate antibody-dr
Figure 1: Pincushion plant (Diapensia lapponica) in bloom, growing in alpine rocky areas. Its distri
April 17, 15:30
New Method Enables Structural Determination of Diverse Phenolic Compounds from a Tiny Alpine Flower Sample
Hyuga Hirano (United Graduate School of Agricultural Science, Tokyo University of Agriculture and Technology, and collaborative graduate student at the National Museum of Nature and Science (President
April 16, 15:30
Invivoscribe Announces the PrepQuant™ System, an Integrated Sample Preparation Platform that Standardizes and Streamlines Pre-Analytical Workflows
Invivoscribe®, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced the launch of the PrepQuant™ System, a novel sample preparation platform that int
April 16, 14:19
Ferring Pharmaceuticals and Gallup Announce Landmark Global Public Attitudes Study on Fertility and Family-Building
Ferring Pharmaceuticals and Gallup today announced the Ferring Global Fertility Monitor, a global study on the factors influencing people’s fertility choices, at the 2026 Annual Convening of Semafor W
April 16, 14:12
Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+™, Powered by Its Next-Generation TriHex Technology® Regenerative Platform
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Regenerating Skin Nectar with TriHex+™, the newest innovation from Alastin, a leader in peptide-based reg
April 15, 08:40
Samsung Bioepis Initiates Phase 1 Clinical Trial for SBE303, Nectin-4 Targeting Antibody-Drug Conjugate (ADC) Candidate
Samsung Bioepis Co., Ltd. announced today the initiation of Phase 1 clinical trial for SBE303. SBE303 is Samsung Bioepis’s first novel antibody-drug conjugate (ADC) candidate engineered to bind to Nec
IFF showcases wellness innovation for beauty.
April 14, 10:00
IFF Explores the Science Behind Well-Being at In‑Cosmetics Global 2026
IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients and health & biosciences—will showcase scent and bioscience innovations focused on wellness and sustainability at In‑Cosmetics
Clean Cells and Naobios Showcase Complete End-to-End Viral Vaccines and Vector Solutions at Bio Kore
April 13, 11:00
Clean Cells and Naobios Showcase Complete End-to-End Viral Vaccines and Vector Solutions at Bio Korea 2026
Clean Cells (https://clean-cells.com/), a leading biopharmaceutical quality control services provider specializing in biologics GMP testing, and Naobios (https://www.naobios.com/), a CDMO (Contract De
April 10, 15:35
Byondis Appoints Christoph Korpus, PhD, MBA as Chief Executive Officer
Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces today the appointment of Christoph Korpus, PhD, MBA, as Chief Executiv
April 09, 14:40
Interim Data From Two Ongoing Investigator-initiated Trials Highlight the Role of Sculptra® and Restylane® in Addressing Aesthetic Changes Associated With Weight Loss Medications and Menopause
Galderma (SIX: GALD), the pure-play dermatology category leader, today welcomes new data from two IITs, demonstrating the power of Sculptra - the first proven regenerative biostimulator - and the comp
April 08, 15:30
Variational AI Releases Enki 4: Major Update to Foundation Model for Small-Molecule Drug Discovery
Variational AI today announced the release of Enki™ 4, a major update to its generative AI platform for small-molecule drug discovery. The release of the fourth generation of Enki™ delivers significan
April 03, 13:30
VDYNE Receives FDA Approval to Initiate the TRIVITA[1] IDE Pivotal Trial of Transcatheter Tricuspid Valve Replacement System
VDYNE, Inc. (“VDYNE” or “the Company”), a privately held medical device company developing next generation transcatheter valve replacement technologies, today announced that the U.S. Food & Drug Admin
25 per page50 per page75 per page100 per page